Uncovering Naringin's Anticancer Mechanisms in Glioblastoma Via Molecular Docking and Network Pharmacology Approaches

Overview

Journal Sci Rep

Specialty Science

Date 2024 Sep 14

PMID 39277626

Authors

Arunraj Tharamelveliyil Rajendran

Gupta Dheeraj Rajesh

Harsha Ashtekar

Anusha Sairam

Pankaj Kumar

Anoop Narayanan Vadakkepushpakath

Affiliations

Soon will be listed here.

Abstract

Naringin, a flavonoid, exhibits diverse therapeutic properties and has been proven to exert cytotoxic effects on cancer cells. Nevertheless, the precise mechanism of naringin maintaining its cytotoxic effect on glioblastoma (GBM) remains unknown. Thus, the current study aimed to establish a plausible cellular mechanism for Naringin's inhibition of GBM. We employed various system biology techniques to forecast the primary targets, including gene ontology and cluster analysis, KEGG enrichment pathway estimation, molecular docking, MD (molecular dynamic) simulation and MMPBSA analysis. Glioblastoma target sequences were obtained via DisGeNet and Therapeutic Target Prediction, aligned with naringin targets, and analyzed for gene enrichment and ontology. Gene enrichment analysis identified the top ten hub genes. Further, molecular docking was conducted on all identified targets. For molecular dynamics modelling, we selected the two complexes that exhibited the most docking affinity and the two most prominent genes of the hub identified through analysis of the enrichment of genes. The PARP1 and ALB1 signalling pathways were found to be the main regulated routes. Naringin exhibited the highest binding potential of - 12.90 kcal/mol with PARP1 (4ZZZ), followed by ABL1 (2ABL), with naringin showing a - 8.4 kcal/mol binding score, as determined by molecular docking. The molecular dynamic approach and MM-PBSA investigation along with PCA study revealed that the complex of Naringin, with 4ZZZ (PARP1) and, 2ABL (ABL1), are highly stable compared to that of imatinib and talazoparib. Analyses of the signalling pathway suggested that naringin may have anticancer effects against GBM by influencing the protein PARP and ALB1 levels. Cytotoxicity assay was performed on two different glioblastoma cell lines C6 and U87MG cells. Naringin demonstrates a higher cytotoxic potency against U87MG human glioblastoma cells compared to C6 rat glioma cells.

Citing Articles

Molecular Docking, Bioinformatic Analysis, and Experimental Verification for the Effect of Naringin on ADHD: Possible Inhibition of GSK-3β and HSP90.

Mokhtar H, Zaitone S, El-Sayed K, Lashine R, Ahmed N, Moursi S Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598348 PMC: 11597433. DOI: 10.3390/ph17111436.

References

Vollmann-Zwerenz A, Leidgens V, Feliciello G, Klein C, Hau P . Tumor Cell Invasion in Glioblastoma. Int J Mol Sci. 2020; 21(6). PMC: 7139341. DOI: 10.3390/ijms21061932. View

Seystahl K, Gramatzki D, Roth P, Weller M . Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. Expert Opin Pharmacother. 2016; 17(9):1259-70. DOI: 10.1080/14656566.2016.1176146. View

Xiao B, Zhou X, Ye M, Lv S, Wu M, Liao C . MicroRNA‑566 modulates vascular endothelial growth factor by targeting Von Hippel‑Landau in human glioblastoma in vitro and in vivo. Mol Med Rep. 2015; 13(1):379-85. DOI: 10.3892/mmr.2015.4537. View

Vasileva N, Ageenko A, Dmitrieva M, Nushtaeva A, Mishinov S, Kochneva G . Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma. Life (Basel). 2021; 11(10). PMC: 8538059. DOI: 10.3390/life11101084. View

Chamberlain M . Treatment options for glioblastoma. Neurosurg Focus. 2006; 20(4):E19. DOI: 10.3171/foc.2006.20.4.12. View

Ricklefs F, Alayo Q, Krenzlin H, Mahmoud A, Speranza M, Nakashima H . Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018; 4(3):eaar2766. PMC: 5842038. DOI: 10.1126/sciadv.aar2766. View

Xi Z, Wang P, Xue Y, Shang C, Liu X, Ma J . Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget. 2017; 8(15):24949-24963. PMC: 5421901. DOI: 10.18632/oncotarget.15327. View

Shah F, Salman S, Idrees J, Idrees F, Shah S, Khan A . Current Progress of Phytomedicine in Glioblastoma Therapy. Curr Med Sci. 2021; 40(6):1067-1074. DOI: 10.1007/s11596-020-2288-8. View

Tharamelveliyil Rajendran A, Rajesh G, Kumar P, Shivam Raju Dwivedi P, Shastry C, Vadakkepushpakath A . Selection of potential natural compounds for poly-ADP-ribose polymerase (PARP) inhibition in glioblastoma therapy by in silico screening methods. Saudi J Biol Sci. 2023; 30(7):103698. PMC: 10362462. DOI: 10.1016/j.sjbs.2023.103698. View

10.

Stabrauskiene J, Kopustinskiene D, Lazauskas R, Bernatoniene J . Naringin and Naringenin: Their Mechanisms of Action and the Potential Anticancer Activities. Biomedicines. 2022; 10(7). PMC: 9313440. DOI: 10.3390/biomedicines10071686. View

11.

Cirmi S, Ferlazzo N, Lombardo G, Maugeri A, Calapai G, Gangemi S . Chemopreventive Agents and Inhibitors of Cancer Hallmarks: May Citrus Offer New Perspectives?. Nutrients. 2016; 8(11. PMC: 5133085. DOI: 10.3390/nu8110698. View

12.

Aroui S, Aouey B, Chtourou Y, Meunier A, Fetoui H, Kenani A . Naringin suppresses cell metastasis and the expression of matrix metalloproteinases (MMP-2 and MMP-9) via the inhibition of ERK-P38-JNK signaling pathway in human glioblastoma. Chem Biol Interact. 2016; 244:195-203. DOI: 10.1016/j.cbi.2015.12.011. View

13.

Ding S, Wang P, Pang X, Zhang L, Qian L, Jia X . The new exploration of pure total flavonoids extracted from as a new therapeutic agent to bring health benefits for people. Front Nutr. 2022; 9:958329. PMC: 9582534. DOI: 10.3389/fnut.2022.958329. View

14.

Jeong J, Kim H, Choi J . In Silico Molecular Docking and In Vivo Validation with to Discover Molecular Initiating Events in Adverse Outcome Pathway Framework: Case Study on Endocrine-Disrupting Chemicals with Estrogen and Androgen Receptors. Int J Mol Sci. 2019; 20(5). PMC: 6429066. DOI: 10.3390/ijms20051209. View

15.

Ahmed A, Aziz M, Ejaz S, Ali Channar P, Saeed A, Zargar S . Design, Synthesis, Kinetic Analysis and Pharmacophore-Directed Discovery of 3-Ethylaniline Hybrid Imino-Thiazolidinone as Potential Inhibitor of Carbonic Anhydrase II: An Emerging Biological Target for Treatment of Cancer. Biomolecules. 2022; 12(11). PMC: 9687900. DOI: 10.3390/biom12111696. View

16.

Xi L, Zhou F, Ji W, Zhu W, Ruan J, Zhang Y . Potential Plasma Metabolic Biomarkers of Tourette Syndrome Discovery Based on Integrated Nontargeted and Targeted Metabolomics Screening Plasma Metabolic Biomarkers of TS. Evid Based Complement Alternat Med. 2023; 2022:5080282. PMC: 9894715. DOI: 10.1155/2022/5080282. View

17.

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M . KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2022; 51(D1):D587-D592. PMC: 9825424. DOI: 10.1093/nar/gkac963. View

18.

Kanehisa M . Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019; 28(11):1947-1951. PMC: 6798127. DOI: 10.1002/pro.3715. View

19.

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

20.

van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark A, Berendsen H . GROMACS: fast, flexible, and free. J Comput Chem. 2005; 26(16):1701-18. DOI: 10.1002/jcc.20291. View